212 related articles for article (PubMed ID: 37001951)
1. Hepatic Encephalopathy: Diagnostic Tools and Management Strategies.
Badal BD; Bajaj JS
Med Clin North Am; 2023 May; 107(3):517-531. PubMed ID: 37001951
[TBL] [Abstract][Full Text] [Related]
2. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.
Jesudian AB; Ahmad M; Bozkaya D; Migliaccio-Walle K
J Manag Care Spec Pharm; 2020 Jun; 26(6):750-757. PubMed ID: 32463782
[TBL] [Abstract][Full Text] [Related]
4. Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments.
Pun CK; Huang HC; Chang CC; Hsu SJ; Huang YH; Hou MC; Lee FY
J Chin Med Assoc; 2024 Mar; 87(3):245-251. PubMed ID: 38109364
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy.
Moon AM; Kim HP; Jiang Y; Lupu G; Bissram JS; Barritt AS; Tapper EB
Am J Gastroenterol; 2023 Feb; 118(2):284-293. PubMed ID: 36730910
[TBL] [Abstract][Full Text] [Related]
7. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
Prakash RK; Kanna S; Mullen KD
Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
[TBL] [Abstract][Full Text] [Related]
8. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
Hudson M; Schuchmann M
Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
[TBL] [Abstract][Full Text] [Related]
9. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.
Patidar KR; Bajaj JS
Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2048-61. PubMed ID: 26164219
[TBL] [Abstract][Full Text] [Related]
10. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
Rahimi RS; Brown KA; Flamm SL; Brown RS
Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
[TBL] [Abstract][Full Text] [Related]
11. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
12. Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.
Moran S; López-Sánchez M; Milke-García MDP; Rodríguez-Leal G
World J Gastroenterol; 2021 Jun; 27(22):3050-3063. PubMed ID: 34168407
[TBL] [Abstract][Full Text] [Related]
13. Disaccharides in the treatment of hepatic encephalopathy.
Sharma P; Sharma BC
Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
[TBL] [Abstract][Full Text] [Related]
14. Management of hepatic encephalopathy in Germany: a survey among physicians.
Labenz C; Adarkwah CC; Wörns MA; Miehlke S; Hofmann WP; Buggisch P; Galle PR; Frieling T; Labenz J
Z Gastroenterol; 2020 Jan; 58(1):49-56. PubMed ID: 31931540
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
16. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
Flamm SL
Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of hepatic encephalopathy.
Shawcross DL
Br J Nurs; 2018 Feb; 27(Sup3):S7-S13. PubMed ID: 29411990
[TBL] [Abstract][Full Text] [Related]
18. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy.
Wang Z; Chu P; Wang W
Drug Des Devel Ther; 2019; 13():1-11. PubMed ID: 30587923
[TBL] [Abstract][Full Text] [Related]
19. The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study.
De Graeve J; Vanderstraeten E; Delvaeye T; De Lepeleere S; De Somer T; Van Steenkiste C
Acta Gastroenterol Belg; 2022; 85(3):433-437. PubMed ID: 35833904
[TBL] [Abstract][Full Text] [Related]
20. Optimal treatment of hepatic encephalopathy.
Waghray A; Waghray N; Kanna S; Mullen K
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
